A Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IDX184 After Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2015
At a glance
- Drugs IDX 184 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme
- 04 May 2009 Results presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009).
- 26 Apr 2009 Results presented at EASL 2009.
- 10 Dec 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.